###### Significance of this study

What is already known about this subject?
=========================================

-   Adipose tissue metabolism and vasculature is impaired and inflammation increased in type 2 diabetes and obesity. Exercise training has beneficial effects on adipose tissue, but little is known about the effect on glucose and free fatty acid (FFA) metabolism.

What are the new findings?
==========================

-   Already short-term training improves adipose tissue glucose and fatty acid metabolism especially in visceral adipose tissue despite the baseline glucose tolerance and sex. This study proposes that SIT improves visceral adipose tissue insulin-stimulated glucose uptake more efficiently than MICT, whereas MICT is preferable for visceral adipose tissue FFA uptake.

-   After 2 weeks of exercise training, improvements could already be seen in glucose and fatty acid metabolism especially in visceral adipose tissue despite the baseline glucose tolerance and sex.

-   This study proposes that sprint interval training (SIT) improves visceral adipose tissue insulin-stimulated glucose uptake more efficiently than moderate-intensity continuous training (MICT), whereas MICT is preferable for improvements in visceral adipose tissue FFA uptake.

-   Training decreases adipose tissue FFA uptake and the expression of FATB4, CD36 and ANGPTL4 mRNA and increases adipose tissue vascularization in insulin-resistant participants.

How might these results change the focus of research or clinical practice?
==========================================================================

-   Connections between adipose tissue and other organs should be studied in more detail. This study also strengthens the potential of exercise training in the prevention of type 2 diabetes.

Introduction {#s1}
============

White adipose tissue has long been recognized as the main site for the storage of excess energy delivered from food. Adipose tissue is also an endocrine organ, which regulates glucose and lipid metabolism and secretes a large number of hormones and cytokines.[@R1] In obesity and insulin resistance (IR), the metabolism of adipose tissue deteriorates and this is indicated by adipocyte hypertrophy and hyperplasia, macrophage infiltration, impaired insulin signaling and IR.[@R1] Impaired adipose tissue metabolism leads to the release of inflammatory adipokines and large amounts of free fatty acids (FFAs) resulting in the accumulation of ectopic fat and lipotoxicity in non-adipose tissues, such as muscle, liver and pancreas.[@R1]

Previous animal and human studies have shown that regular exercise training has beneficial effects on adipose tissue. Regular exercise training has been shown, both in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), to reduce adipose tissue mass,[@R4] adipocyte hypertrophy, adipose tissue inflammation[@R6] and increase mitochondrial function and biogenesis[@R7] in humans and rodents. A recent study showed that exercise training influences (increase/decrease) global expression of inflammation-related factors especially in abdominal SAT especially in dysglycemic men.[@R6] Emerging evidence from preclinical studies suggest that training-induced effects on adipose tissues are tissue specific.[@R8] For example, VAT has shown to be more responsive to exercise training due to its higher level of adrenergic activation.[@R7] In addition, our previous clinical studies using positron emission tomography (PET) have shown that VAT is metabolically more active than SAT with both a higher glucose uptake[@R11] and fatty acid uptake.[@R12] However, studies comparing exercise training-driven adaptions to SAT and VAT metabolism in humans are more limited.

It is well known that exercise training leads to a decrease in plasma insulin levels and circulating catecholamines and seems to lead to increase in lipolysis in relation to exercise intensity.[@R7] However, during high-intensity training, it has been suggested that the reduction in adipose tissue blood flow leads to a decrease in adipose tissue FFA release.[@R15] Sprint interval training (SIT) has been the focus of research as a time-saving training method and it has been suggested to be superior compared with moderate-intensity continuous training (MICT) in improving whole-body glucose metabolism and maximal aerobic capacity (VO~2peak~).[@R16] To our knowledge, no previous studies have investigated whether SIT or MICT is preferable in improving the depot-specific adipose tissue metabolism in insulin-resistant (IR) participants.

The aim of the present study was to investigate the effects of 2 weeks of supervised, progressive exercise training on VAT and SAT glucose as well as fatty acid metabolism in healthy participants and participants with IR. Furthermore, using abdominal SAT biopsies, we were able to determine the training-induced effects on adipocyte cell size, adipose tissue vascularization and adipose tissue gene expression markers related to lipolysis, inflammation, adipogenesis, and glucose and FFA transport. Currently it is unclear whether the training responses on adipose tissue metabolism are similar between healthy and IR participants, and whether SIT is superior to MICT.[@R18] The outcome data were also compared between IR men and women as previous studies have shown sex differences in adipose tissue metabolism.[@R20] Thus, the present study examined in middle-aged, sedentary participants whether training responses are similar in different adipose tissues:

1.  Between healthy and IR participants?

2.  After SIT compared with MICT in IR participants?

3.  Between women and men in IR participants?

We hypothesized that already 2 weeks of exercise training would induce beneficial changes in adipose tissue glucose and fatty acid metabolism both in healthy and IR participants and these changes would be associated with reduced adipocyte cell size and improved gene expression profile. We also hypothesized that these improvements would be seen both after SIT and MICT regardless of the sex.

Research design and methods {#s2}
===========================

Ethics {#s2-1}
------

The study was part of a larger clinical trial (NCT01344928) entitled "The effects of short-term high-intensity interval training on tissue glucose and fat metabolism in healthy participants and in patients with type 2 diabetes." The primary objective of the larger trial was to study the effects of exercise training on skeletal muscle and the outcomes of the present study are explorative. The results related to whole-body insulin sensitivity (M-value), aerobic fitness and basic characteristics in this manuscript have already been published.[@R21] The main parameters of the present study, adipose tissue metabolism, cell size and gene expression have not been published before either in healthy or in IR subjects. The study was performed at the Turku PET Centre, University of Turku and Turku University Hospital (Turku, Finland) and the Paavo Nurmi Centre (Turku, Finland) between March 2011 and September 2015.

Participants {#s2-2}
------------

Middle-aged, physically inactive, healthy men participants (n=28) and woman and men participants with IR (n=26) were recruited for the study via newspaper advertisements, personal contacts, and electronic and traditional bulletin boards. The inclusion criteria for the healthy participants were men sex, age 40--55 years, body mass index (BMI) 18.5--30 kg/m^2^, VO~2peak~ \<40 mL/kg/min and normal glycemic control.[@R25] The allowed physical activity was limited to twice a week or less. A candidate was excluded if he or she had a condition which could potentially endanger their health during the study or interfere with the interpretation of the results as previously explained in detail.[@R21] For the IR participants, the inclusion criteria were the same as for the healthy participants except for BMI 18.5--35 kg/m^2^ and an impaired glucose tolerance (IGT) according to the criteria of the American Diabetes Association (ADA),[@R25] an glycated hemoglobin (HbA1c) of less than 7.5% and no insulin treatment in the cases of type 2 diabetes.

Based on the oral glucose tolerance tests (OGTTs), all 26 subjects met the criteria of IR set by ADA[@R25] and had an HbA1c less than 7.5%. At the time of screening, four participants were newly diagnosed with type 2 diabetes and had no previous medication. For the other 11 participants with type 2 diabetes, the median diabetes duration was 4.2 years and they were treated by oral hypoglycemic agents (11 with metformin, 5 with sitagliptin and 1 with glimepiride). Antidiabetic medication was withheld for 48 hours and the participants were asked to avoid any exhausting exercise 48 hours prior to the measurements. All participants were asked not to change their habitual dietary intake during the study period. There was a total of seven dropouts in the study ([figure 1](#F1){ref-type="fig"}).

![Participant flow diagram. The analyses were carried out using the intention-to-treat principle and hence included all the randomized participants. MICT, moderate-intensity continuous training; SIT, sprint interval training; T2DM, type 2 diabetes mellitus.](bmjdrc-2019-000830f01){#F1}

Study design {#s2-3}
------------

The physical examination, OGTT, VO~2max~ test, MRI, hyperinsulinemic clamp and PET with 14(R, S)-\[18F\]fluoro-6-thia-heptadecanoic acid (FTHA) and 2-\[18F\]fluoro-2-deoxy-D-glucose (FDG) tracers were performed before and after the training intervention as described in [figure 2](#F2){ref-type="fig"}. Randomization either into the SIT or MICT group was done using a 1:1 allocation ratio and was performed separately for the healthy and prediabetic or type 2 diabetic participants with random permuted blocks, and this has been previously described in detail.[@R21] Power calculations were calculated based on the main outcomes of the whole trial (muscle glucose uptake) and have been described previously.[@R22] No sample size calculation were specifically performed on the outcome measurements of the present study.

![The study design. \[18F\] FDG, 2-\[18F\]fluoro-2-deoxy-D-glucose; \[18F\] FTHA, 14(R, S)-\[18F\]fluoro-6-thia-heptadecanoic acid; FFA, free fatty acid; MICT, moderate-intensity continuous training; OGTT, oral glucose tolerance test; PET, positron emission tomography; SIT, sprint interval training; VO~2max~, maximal aerobic capacity.](bmjdrc-2019-000830f02){#F2}

Exercise intervention {#s2-4}
---------------------

Participants participated in a 2-week supervised, progressive training intervention, which included six training sessions of either SIT or MICT. The duration of the intervention was based on previous studies showing improvements in aerobic fitness and insulin sensitivity after only six training sessions.[@R16] Each session was performed in laboratory conditions at the Turku PET Centre under the supervision of a member of the study group.

Each MICT session consisted of 40--60 min of cycling at a moderate intensity, which was determined as 60% of the measured VO~2peak~ workload monitored by corresponding heart rate (Tunturi E85; Tunturi Fitness, Almere, The Netherlands) based on previous MICT protocols. The duration of the MICT increased progressively starting with 40 min and increasing by 10 min every other session up to 60 min. SIT sessions consisted of 4--6×30 s of all-out cycling bouts (Monark Ergomedic 894E; MONARK, Vansbro, Sweden), with a 4 min recovery between each bout. The number of bouts increased progressively starting with four bouts and increasing by one every other session up to six bouts per session. The training load was individually determined (for healthy participants 7.5% of whole-body weight in kilogram, for IR participants 10% of lean body mass in kilogram).

Magnetic resonance imaging {#s2-5}
--------------------------

VAT and abdominal SAT depot masses were measured with MRI (Philips Gyroscan Intera 1.5 T CV Nova Dual scanner, Philips Medical Systems). Whole-body (from head to knee) axial T1-weighted dual-fast field echo images (TE 2.3 and 4.7 ms, TR 120 ms, slice thickness 10 mm without gap) were obtained and analyzed using sliceOmatic software V.4.3 (<http://www.tomovision.com/products/sliceomatic.html>). To obtain the tissue mass, the pixel surface area was multiplied by slice thickness and density of adipose tissue 0.9196 kg/L. Unfortunately, we were not able to measure femoral SAT mass as the MRI was not performed on the whole femoral region.

Positron emission tomography {#s2-6}
----------------------------

Participants underwent four PET sessions: one \[^18^F\]FTHA PET and one \[^18^F\]FDG PET before and after the training intervention. An euglycemic-hyperinsulinemic clamp was performed during \[^18^F\]FDG PET scanning day after a 10-hour fast based on the original protocol by Defronzo *et al*.[@R30] During the first 4 min, a primed-constant insulin (Actrapid, 100 U/mL; Novo Nordisk, Bagsvaerd, Denmark) infusion was started at a rate of 120 mU/m^2^/min of body surface area. After the first 4 min, the infusion rate was decreased to 80 mU/m^2^/min for 3 min, and then further decreased to 40 mU/m^2^/min for the rest of the clamp. Normoglycemia was adjusted with 20% glucose infusion. Plasma glucose concentration was determined every 5--10 min from arterialized venous blood, and insulin and FFA concentrations were determined every 30 and 60 min, respectively. The M-value was calculated from the glucose infusion rate and the measured glucose values collected when the participants had reached a steady state during the PET scan. The participants were positioned supine in a PET scanner (GE Discovery ST System, Milwaukee, Wisconsin, USA). To measure the plasma radioactivity for tracer input function, arterialized venous blood samples were collected repeatedly during \[^18^F\]FTHA and \[^18^F\]FDG scanning. Plasma radioactivity was measured with an automatic gamma counter (Wizard 1480 3"; Wallac, Turku, Finland).

Regions of interest (ROIs) {#s2-7}
--------------------------

All the imaging data were corrected for dead time, decay and measured photon attenuation, and then reconstructed with scanner software using a 3D-ordered subset expectation maximization (3D-OSEM). Carimas 2.9 software (Turku PET Centre, Turku, Finland) was used to analyze all the acquired PET-CT images. The ROIs were drawn manually on abdominal white SAT, on planes superior to the umbilicus, on VAT at the level of the umbilicus and on femoral subcutaneous tissue at the midregion of the thigh using the CT as an anatomical reference. The rate constant (Ki) for the uptake of radiotracer (\[^18^F\]FTHA, \[^18^F\]FDG) into the cells was calculated using tissue time activity curves obtained from the abdominal SAT, VAT and femoral SAT using a fractional uptake method. Regional glucose and FFA uptakes were calculated by multiplying regional specific K~i~ by corresponding plasma glucose or FFA concentration, respectively. For glucose uptake the products were further divided by a lumped constant value of 1.0 and a tissue density of 0.9136 in adipose tissue.[@R31]

Adipose tissue biopsy and processing {#s2-8}
------------------------------------

Adipose tissue biopsies were performed under local anesthesia after all PET scannings had been performed. Abdominal SAT was biopsied 6--8 cm laterally from the umbilicus under local anesthesia. For the gene expression analyses, the tissue sample was snap frozen in liquid nitrogen and stored at −70°C. For adipocyte cell size analyses tissue sample was fixed overnight in 4% paraformaldehyde (PFA) and embedded in paraffin for histological sections.

RNA isolation, complementary DNA (cDNA) synthesis and reverse transcriptase PCR {#s2-9}
-------------------------------------------------------------------------------

To isolate RNA from the human abdominal SAT, a piece of the tissue was homogenized in 700 µL of TRIsure reagent (Bioline, USA) using the bead-based tissue homogenizer PowerLyzer24 (MO BIO Laboratories, USA). The genomic DNA (gDNA) in the lysate was removed using a gDNA eliminator spin column and the RNA was purified using RNeasy plus micro kit (Qiagen, no: 74034) according to the manufacturer's instructions. RNA was reverse transcribed into cDNA with a high-capacity cDNA reverse transcription kit (Applied Biosystems, no: 4368814), and gene expression was analyzed using a FastStart Universal SYBR green master mix (Sigma-Aldrich, no: 04913914001) kit. The gene expression assay was performed in Bio-Rad C1000 thermal cycler according to the standardized protocol of the quantitative PCR master mix supplier. The quantification cycle (Cq) values of the technical triplicates were collected using Bio-Rad CFX Manager software (v3.1). The data were imported to qBase plus software (Biogazelle, <https://www.qbaseplus.com>), and the Cq average of each sample were normalized to the housekeeping genes 36B4 and YWHAZ. The mRNA expression level was calculated and presented as fold a change (control=1). The human primer sequences are listed in [online supplementary material](#SP1){ref-type="supplementary-material"}.
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Immunohistochemistry {#s2-10}
--------------------

Eight-micrometer-thick abdominal SAT sections were deparaffinized, incubated in high pH antigen retrieval buffer, rinsed with phosphate-buffered saline (PBS) and blocked with DIM buffer (5% normal donkey serum, 0.2% bovine serum albumin, 0.3% Triton X-100% and 0.005% sodium azide). The sections were incubated overnight at 4°C with the following primary antibodies: mouse anti-human CD31 (no: M0823; DAKO) and guinea pig anti-human perilipin (no: 20R-PP004; Fiztgerald) to stain vasculature and adipocytes, respectively. The Alexa-conjugated 488 and 594 secondary antibodies (Molecular Probes, Invitrogen) were used to detect primary antibody signal. The sections were stained for DAPI, rinsed with PBS, fixed with 1% PFA dissolved in PBS for 5 min at 4°C. The stained sections were mounted using VECTASHIELD Hardset Antifade Mounting Medium (H-1400; Vector Laboratories). Images of 40× were acquired using an Axio imager upright epifluorescence microscope (Carl Zeiss). The images were initially adjusted for threshold and area fraction tool was used to quantify the vasculature area (%). The adipocyte size was measured using a cell profiler pipeline on a in Cell Profiler image analysis platform (Carpenter Lab, Broad Institute, <https://www.cellprofiler.org>).[@R32]

Biomarkers in plasma {#s2-11}
--------------------

Concentrations of tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor D and A (VEGF-A) and also, C-reactive protein (CRP) were measured by multiplex bead assay analysis (Luminex Performance Assay Multiplex Kit; Procarta Immunoassay Affymetrix, Santa Clara, California, USA) according to the manufacturer's instructions. Samples were analyzed with a LUMINEX 200 using Luminex xPonent software (Luminex, USA).

Other measurements {#s2-12}
------------------

Aerobic capacity was determined with a VO~2max~ cycling ergometer test (ergoline 800 s; VIASYS Healthcare, Germany) at the Paavo Nurmi Center (Turku, Finland) about 1 week before the first training session and 96 hours after the last training session. The VO~2max~ test has previously been described in detail by Kiviniemi *et al*.[@R33] Body composition was determined using the bioimpedance method (InBody 720; Mega Electronics, Kuopio, Finland).

Statistical analysis {#s2-13}
--------------------

The normal distribution of the variables was tested first with the Shapiro-Wilk test and evaluated visually. After the hierarchical mixed linear models, the normal distribution of the studentized residuals was evaluated visually using Q-Q plots. Logarithmic (log10) or square root transformations were performed when appropriate to achieve a normal distribution. Statistical analyses were performed using hierarchical mixed linear models with compound symmetry covariance structure. First, the differences between healthy and IR men were studied with the model, which included one within-factor term (time, indicating the overall mean change between baseline and measurement after the intervention, used repeated statement in SAS), one between-factor term (IR; healthy and IR men) and one interaction term (time×IR, indicating whether mean change during the study was different between healthy and IR men). IR women were completely excluded when comparing the effects of exercise in healthy and IR participants to avoid mixing the effects of sex and glucose intolerance. Second, in IR participants, differences between SIT and MICT, including both men and women, were studied using a model that included a within-factor time, a between-factor group (SIT and MICT) and interaction terms (time×training, whether the mean change was different in the SIT and MICT groups). Third, differences between men and women in IR participants were studied using a model that included a within-factor group (men and women) and interaction terms (time × sex, whether mean change was different between men and women). Healthy subjects were excluded from the investigation of exercise regimen (SIT vs MICT) and sex, as we were specifically interested about whether the training responses are different after SIT and MICT in IR population known to have metabolic impairments. In all analyses, time, training, sex and insulin level (healthy vs IR) were handled as fixed effects.

The analyses were carried out using the intention-to-treat principle and included all the randomized participants. Missing data points were accounted for by using a restricted maximum likelihood estimation within the linear mixed models. Correlations were calculated using Pearson's correlation (Spearman's rank correlation for non-normally distributed data). The statistical tests were performed as two sided and the level of statistical significance was set at 0.05. The analyses were performed using an SAS System, V.9.4 for Windows (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Healthy versus insulin-resistant (IR) men {#s3-1}
-----------------------------------------

Of the 26 IR participants, 16 had type 2 diabetes and 10 impaired fasting glucose and/or IGT. In the MICT group, all participants attended all training sessions and in the SIT group 21 participants (12 healthy, 9 IR) attended all six sessions and three participants (1 heathy, 2 IR) attended five sessions. The total training time in the SIT group was on average 14±1.3 min as all participants were not able to perform all exercise bouts for the entire 30 s time. The average number of bouts for heathy was 27.5 and for IR 28.6 when the maximum number of bouts was 30 (4+4+5+5+6+6). The average power for the MICT group was 127.8±24.3 W (healthy 133.2±17.3 W and IR 117.7±32.6 W) and for the SIT group 427.3±62.3 W (healthy 407.2±47.8 and IR 449.0±75.9 W) The dropouts are not included in these calculations.

The basic characteristics are presented as central tendencies in [table 1](#T1){ref-type="table"} and as model-based means in [table 2](#T2){ref-type="table"}. The estimated mean differences, estimated mean ratios and upper and lower confidence intervals (Cls) for the variables are presented in the [online supplementary tables 1 and 2](#SP1){ref-type="supplementary-material"}. The IR men had significantly higher body adiposity, circulating lipid values, impaired glucose homeostasis and aerobic fitness as well as a tendency to have higher CRP levels compared with healthy controls as summarized in [table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}. Notably, the VAT and abdominal SAT masses were higher in IR men than in healthy men (38% and 36%, respectively). Both interventions were associated with reduced body adiposity and improved cholesterol values and aerobic fitness both in the healthy and the IR men ([table 2](#T2){ref-type="table"}) but did not have a significant effect on abdominal SAT adipocyte cell size ([figure 4C](#F4){ref-type="fig"}).

###### 

Central tendency and dispersion of the variables in each participant group at the baseline

                             Healthy men   IR men   IR women                       
  -------------------------- ------------- -------- ---------- --------- --------- --------
  Age (years)                49\*          8\*      47         3         54\*      6\*
  Body mass (kg)             83.6          8.8      96.3       12.6      84.5      10.4
  BMI (kg/m^2^)              26.1          2.4      30.4       2.9       30.5      2.5
  Whole body fat (%)         22.6          4.2      28.8       4.8       40.9      4.5
  Abdominal SAT (kg)         4.2           1.4      6.3        2.4       9.33      2.13
  Visceral fat (kg)          2.8           1.5      4.5        1.9       2.51      0.74
  Cholesterol (mmol/L)^\*^   5.00          0.90     4.70\*     1.05\*    5.07      0.55
  HDL cholesterol (mmol/L)   1.29\*        0.39\*   1.23       0.29      1.50      0.35
  LDL cholesterol (mmol/L)   3.14          0.80     2.71       0.82      2.96      0.60
  Triglycerides (mmol/L)     0.99          0.31     1.60\*     1.40\*    1.34      0.50
  f-FFA                      0.70          0.19     0.68       0.17      0.97      0.12
  HbA1c (mmol/mol)           36.9          3.8      39.6       5.6       39.5      2.4
  HbA1c (%)                  5.5           2.5      5.8        2.6       5.8       2.4
  f-glucose (mmol/L)         5.47          0.40     6.95\*     1.33\*    6.80      0.59
  f-insulin (mmol/L)         5.00\*        2.50\*   16.50\*    11.00\*   12.00\*   5.01\*
  M-value (µmol/kg/min)      35.3          14.5     17.5       10.6      19.6      12.2
  VO~2peak~ (mL/kg/min)      34.2          4.1      29.3       3.7       23.8      3.9

For normally distributed parameters, measure of central tendency is expressed as arithmetic mean and dispersion as SD. For non-normally distributed parameters, measure of central tendency is expressed as median and dispersion as IQR (the difference between 75th and 25th percentiles).

\*Non-normally distributed parameters.

BMI, body mass index; f-FFA, fasting free fatty acid; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IR, insulin resistance; LDL, low-density lipoprotein; M-value, whole-body insulin sensitivity; SAT, subcutaneous adipose tissue; VO~2peak~, maximal aerobic capacity.

###### 

Descriptive statistics and results of hierarchical mixed linear models in characteristics of healthy and IR men

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 Healthy men              IR men                   Baseline                 Time                     Time\* IR                   
  ------------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------- ------------- ------
  n                              28                       26                       16                       13                       --            --            --

  Age (years)                    48                       --                       49                       --                       --            --            --

  Body mass (kg)                 83.6 (79.6 to 87.6)      83.3 (79.3 to 87.3)      96.3 (91.0 to 101.7)     96.1 (90.8 to 101.5)     **\<0.001**   0.22          0.78

  BMI (kg/m^2^)                  26.1 (25.1 to 27.1)      26.0 (25.0 to 27.0)      30.4 (29.1 to 31.8)      30.4 (29.0 to 31.8)      **\<0.001**   0.18          0.69

  Whole-body fat (%)**^\*^**     22.1 (20.5 to 23.9)      21.1 (19.5 to 22.7)      28.4 (25.6 to 31.5)      27.6 (24.9 to 30.7)      **\<0.001**   **\<0.001**   0.30

  Abdominal SAT (kg)             4.1 (3.5 to 4.7)         4.0 (3.4 to 4.6)         6.1 (5.18 to 7.18)       6.0 (5.1 to 7.1)         **\<0.001**   **0.04**      0.84

  Visceral fat (kg)†             2.5 (2.0 to 3.2)         2.4 (1.9 to 3.08)        4.3 (5.4 to 3.4)         4.1 (3.1 to 5.1)         **0.002**     **0.002**     0.48

  Cholesterol (mmol/L)^\*^       4.92 (4.57 to 5.29)      4.40 (4.08 to 4.74)      4.71 (4.27 to 5.19)      4.31 (3.90 to 4.77)      0.44          **\<0.001**   0.52

  HDL cholesterol (mmol/L)^\*^   1.37 (1.25 to 1.50)      1.27 (1.15 to 1.39)      1.20 (1.06 to 1.35)      1.09 (0.96 to 1.23)      0.08          **\<0.001**   0.66

  LDL cholesterol (mmol/L)       3.14 (2.85 to 3.43)      2.78 (2.48 to 3.08)      2.73 (2.34 to 3.12)      2.58 (2.18 to 2.98)      0.09          **\<0.001**   0.16

  Triglycerides (mmol/L)^\*^     0.94 (0.81 to 1.11)      0.83 (0.70 to 0.98)      1.70 (1.38 to 2.10)      1.50 (1.19 to 1.90)      **\<0.001**   0.08          0.96

  f-FFA                          0.70 (0.62 to 0.77)      0.62 (0.54 to 0.69)      0.69 (0.60 to 0.78)      0.68 (0.59 to 0.78)      0.86          **0.04**      0.11

  HbA1c (mmol/L)                 36.93 (35.19 to 38.66)   34.72 (32.94 to 36.50)   39.64 (37.33 to 41.96)   37.65 (35.27 to 40.02)   0.07          **\<0.001**   0.81

  HbA1c (%)                      5.5 (5.4 to 5.7)         5.3 (5.2 to 5.5)         5.8 (5.6 to 6.0)         5.6 (5.5 to 5.8)         0.07          **0.001**     0.8

  f-glucose (mmol/L)^\*^         5.44 (5.25 to 5.64)      5.74 (5.52 to 5.96)      7.20 (6.86 to 7.56)      7.16 (6.80 to 7.55)      **\<0.001**   0.15          0.80

  f-insulin (mmol/L)^\*^         4.70 (3.75 to 5.90)      5.85 (4.61 to 7.43)      14.49 (10.72 to 19.57)   13.58 (9.87 to 18.68)    **0.001**     0.37          0.10

  M-value\                       32.2 (26.6 to 39.0)      35.5 (29.2 to 43.2)      14.8 (11.4 to 19.2)      19.2 (14.7 to 25.19)     **\<0.001**   **0.001**     0.1
  (µmol/kg/min)                                                                                                                                                  

  VO~2peak~\                     34.2 (32.7 to 35.7)      35.7 (34.2 to 35.7)      29.4 (27.3 to 31.5)      30.0 (27.9 to 32.1)      **\<0.001**   **0.003**     0.14
  (mL/kg/min)                                                                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

The p-value for "baseline" describes the baseline differences between the healthy (n=28) and IR (n=16) groups. "Time" shows all healthy and IR men after training. "Time\*IR" demonstrates whether there is an interaction between the pre--post change and health status. All the data are presented as model-based means (95% CI). The values are model-based means and CIs translated into the original unit.

Bold values are statistically significant.

\*Logarithmic transformation has been done to the variables to achieve the normal distribution.

†Square transformation to the variables to achieve the normal distribution.

BMI, body mass index; f-FFA, fasting free fatty acid; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IR, insulin resistance; LDL, low-density lipoprotein; M-value, whole-body insulin sensitivity; SAT, subcutaneous adipose tissue; VO~2peak~, maximal aerobic capacity.

![Levels of different markers of (A) inflammation and (B) vascularization in plasma. Markers are visualized in three different comparisons: healthy versus insulin-resistant (IR) men, sprint interval training (SIT) versus moderate-intensity continuous training (MICT) in IR participants and men versus women in IR participants. All data are expressed as means and 95% CIs. \#p\<0.05: difference at baseline. \*p\<0.05: the effect of exercise training over time in the whole group or a subgroup. Model-based means together with 95% CIs are presented. CRP, C reactive protein; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.](bmjdrc-2019-000830f03){#F3}

![(A) Representative images of abdominal subcutaneous adipose tissue (SAT) stained with perilipin for adipocytes and CD31 for blood vessels. (B) Quantification of adipose tissue vasculature from CD31-stained sections. Values are shown in three different comparisons: healthy versus insulin-resistant (IR) men, sprint interval training (SIT) versus moderate-intensity continuous training (MICT) in IR participants and men versus women in IR participants. Data in the figure (B) are expressed as means and 95% CIs. \*p\<0.05, scale bar 100 mm. (C) Adipocyte cell size distribution from the total population of cells in SAT in healthy (A) and IR (B) participants before (white bars) and after (black bars) the intervention. Model-based means together with 95% CIs are presented.](bmjdrc-2019-000830f04){#F4}

At baseline, the IR men had significantly lower glucose uptake (µmol/min/100 g) in their VAT and in their femoral and abdominal SAT than the healthy men (all p\<0.001; [figure 5](#F5){ref-type="fig"}). These baseline differences were not seen when comparing the glucose uptake for each whole tissue mass in VAT and abdominal SAT ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}). Glucose uptake in both VAT (time p\<0.001; [figure 5](#F5){ref-type="fig"}) and femoral SAT (time p\<0.001; [figure 5](#F5){ref-type="fig"}) increased with training, similarly in the healthy and IR men. Only femoral SAT glucose uptake remained lower in the IR men compared with the healthy participants after the intervention.

![Insulin-stimulated glucose uptake (GU) per 100 g of tissue before (white bars) and after (black bars) the training intervention in visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and femoral SAT. Glucose uptake is compared in three different comparisons: healthy versus insulin-resistant (IR) men (blue), sprint interval training (SIT) versus moderate-intensity continuous training (MICT) in IR participants (green) and men versus women in IR participants (red). All data are expressed as means and 95% CIs. \#p\<0.05: difference at baseline, ¤p\<0.0: baseline difference after training, \*p\<0.05: the effect of exercise training over time in the whole group or a subgroup. Model-based means together with 95% CIs are presented.](bmjdrc-2019-000830f05){#F5}

Before the intervention, the IR participants had lower visceral and abdominal SAT fatty acid uptake levels than the healthy men (both 35%, p\<0.001; [figure 6](#F6){ref-type="fig"}) but we found no difference in femoral SAT fatty acid uptake (p=0.3) between the groups. Both in healthy and IR men, training decreased fatty acid uptake in VAT (time p=0.01) and tended to decrease fatty acid uptake in abdominal and femoral SAT depots (time p=0.06 and time p=0.07, respectively). After training, the fatty acid uptake only remained lower in the abdominal SAT of the IR group when compared with the healthy men.

![Fasting free fatty acid uptake (FAU) per 100 g of the tissue before (white bars) and after (black bars) the training intervention in visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT) and femoral SAT. Glucose uptake is compared in three different comparisons: healthy versus insulin-resistant (IR) men (blue), sprint interval training (SIT) versus moderate-intensity continuous training (MICT) in IR participants (green) and men versus women in IR participants (red). All data are expressed as means and 95% CIs. \#p\<0.05: difference at baseline. \*p\<0.05: the effect of exercise training over time in the whole group or a subgroup. Model-based means together with 95% CIs are presented.](bmjdrc-2019-000830f06){#F6}

Of the plasma inflammation and vascularization markers studied, exercise training reduced TNF-α (p=0.02) and VEGF-A (p=0.02) in the whole group with no differences between healthy and IR men ([figure 7](#F7){ref-type="fig"}). We did not observe baseline differences in adipose tissue mRNA expression in genes related to lipolysis, inflammation, adipogenesis and glucose and the FFA transport between IR and healthy participants ([figure 7](#F7){ref-type="fig"}).

![Gene expression of CD36, ANGPTL4, CD68, GLUT4, FABP4 and FASN in abdominal subcutaneous adipose tissue. Genes are visualized in three different comparisons: healthy versus insulin-resistant (IR) men, sprint interval training (SIT) versus moderate-intensity continuous training (MICT) in IR participants and men versus women in IR participants. All data are expressed as means and 95% CIs. \*p\<0.05: the effect of exercise training over time in the whole group or a subgroup. ANGPTL4, angiopoietin-like 4; CD, cluster of differentiation; FABP4, fatty-acid binding protein 4; FASN, fatty acid synthase; GLUT4, glucose transporter type 4; PDK-4, pyruvate dehydrogenase lipoamide kinase isozyme 4; PPAR-γ, peroxisome proliferator-activated receptor gamma. Model-based means together with 95% CIs are presented.](bmjdrc-2019-000830f07){#F7}

SIT versus MICT in IR men and women {#s3-2}
-----------------------------------

No differences were observed in basic characteristics between the SIT and MICT training groups either at baseline or after the intervention ([online supplementary table 3](#SP1){ref-type="supplementary-material"}). For the whole group, training was associated with a decrease in VAT mass, high-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, HbA1c concentrations and increase in whole-body insulin sensitivity without any significant differences being found between the two training modes. When studied according to the exercise mode, only SIT was associated with an increase in the VO~2peak~ (SIT+5% vs MICT 0%, time\*training p=0.047).

Femoral SAT glucose uptake improved with both SIT and MICT (25% and 20%, respectively, time p=0.004). However, in the VAT the training response was different between the two training modes with only SIT increasing VAT glucose uptake (30% vs 4%, time\*training, p=0.03) and only MICT was associated with reduced VAT fatty acid uptake (−30% vs 3%, p=0.01) ([figure 5](#F5){ref-type="fig"}). Interestingly, the differential responses between the two training modes were still present when the VAT glucose uptake and fatty acid uptake were calculated per tissue depot (time\*training, p=0.03 and p=0.007, respectively) ([online supplementary figures 1 and 2](#SP1){ref-type="supplementary-material"}). Additional descriptive statistics and results linear mixed model with repeated measures for characteristics of SIT and MICT training groups in all healthy and IR subjects, including both men and women, are presented in [online supplementary table 4](#SP1){ref-type="supplementary-material"}.

Of the studied genes, we found a significant decrease in CD36 and ANGPTL4 (p=0.042 and p=0.047, respectively) after both training modes ([figure 7](#F7){ref-type="fig"}). In addition, we saw an increase in adipose tissue vascularization after both training modes ([figure 3B](#F3){ref-type="fig"}).

IR men versus IR women {#s3-3}
----------------------

IR women differed markedly from IR men, being older and having significantly higher whole-body fat content, abdominal SAT mass and plasma FFA concentration. However, they had significantly lower VAT mass when compared with IR men ([online supplementary table 5](#SP1){ref-type="supplementary-material"}).

At baseline, VAT glucose uptake and fatty acid uptake (19%, p=0.04 and 37%, p=0.002, respectively) and femoral SAT fatty acid uptake (18%, p=0.02) were significantly higher in women compared with men ([figure 6](#F6){ref-type="fig"}), but no significant baseline difference was found in abdominal SAT glucose uptake ([figure 5](#F5){ref-type="fig"}). Training was associated with an increase in VAT glucose uptake both in men and women (21% and 8%, respectively, time p=0.04) and decreased VAT fatty acid uptake (−15% and −17%, respectively, time p=0.03) with no difference between the sexes. However, only men showed improvement in femoral SAT glucose uptake after exercise training (men 37% vs women 7%, time\*sex p=0.02).

Discussion {#s4}
==========

The aim of the study was to investigate the effects of a 2-week-long supervised, progressive exercise training on adipose tissue metabolism and morphology. The study demonstrates that short-term exercise training was associated with an increase in insulin-stimulated VAT and femoral SAT glucose uptake and reduction in fasting VAT fatty acid uptake both in healthy participants and participants with IR. Interestingly, only SIT was associated with increased VAT glucose uptake, whereas only MICT decreased VAT fatty acid uptake in participants with IR. In addition, we observed an increase in adipose tissue vasculature and a decrease in abdominal SAT CD36 and ANGPTL4 mRNA expression in IR participants after both training modes. As expected,[@R20] we found that women have metabolically more active adipose tissue than men with both higher glucose uptake and fatty acid uptake in VAT and femoral SAT.

Healthy versus IR (men) {#s4-1}
-----------------------

In the present study, glucose uptake (µmol/min/100 g) was 29% lower in VAT, 32% lower in abdominal SAT and 50% lower in femoral SAT in IR participants compared with healthy participants. However, when calculated per tissue depot, glucose uptake in these adipose tissues was similar between healthy and IR participants due to the significantly greater masses of these fat depots in the IR group as also shown previously.[@R11]

Exercise training induced significant improvements in VAT and femoral SAT glucose uptake both in healthy (5% and 18%) and IR participants (21% and 36%), respectively. Studies investigating the effects of training on adipose tissue insulin-stimulated glucose uptake in vivo in humans are scarce. Opposite to our findings, Reichkendler *et al* found a decrease in the insulin-stimulated abdominal SAT glucose uptake rate but no change in VAT or femoral SAT glucose uptake after 11 weeks of endurance training (\>70% VO~2max~) in healthy sedentary moderately overweight men using PET and semiquantitative standard uptake modeling.[@R34] The authors suggested that insulin sensitivity does not increase in non-contracting adipose tissue, similar to those skeletal muscles that are not active during exercise training. They also discussed about the possibility of contracting skeletal muscles signaling to adipose tissue to decrease glucose uptake to maintain the whole-body glucose homoeostasis. Interestingly, we found that when using femoral muscle glucose uptake[@R35] as a covariant, the increase in femoral SAT glucose uptake was no longer significant. This suggests that the observed improvement in femoral SAT glucose uptake is due to the enhancement of muscle glucose uptake facilitating the metabolism of nearby tissues. We also tested the improvement in VAT glucose uptake by taking the glucose uptake of the nearby muscles as a covariate and found no change in the result. However, VAT is not very closely associated with nearby muscles, as these muscles are not working as much as the thigh muscles during exercise. VAT has also been shown to be distinct from other white adipose tissues with higher cellularity and greater glucose uptake per adipocyte which may explain the finding.[@R36]

In humans, SAT insulin-stimulated glucose uptake has been shown to be higher in vitro and in vivo in trained compared with sedentary participants using microdialysis.[@R37] Trained rats have also shown to have a greater relative amount of insulin-sensitive glucose transporters (GLUT4) as well as higher insulin-stimulated glucose transport in adipose tissue compared with sedentary animals.[@R39] In the present study, we did not found any change in abdominal SAT GLUT-4 protein mRNA expression.

It has been previously shown that FABP4 and CD36 expression is upregulated in adipose tissue in participants with impaired insulin sensitivity and type 2 diabetes, associated with increased fatty acid uptake, adipocyte hypertrophy and inflammation.[@R42] A previous FTHA-PET study conducted in our laboratory showed more than 100% higher fasting fatty acid uptake per 100 g in VAT, but not in abdominal SAT, in obese participants with a metabolic syndrome compared with lean participants.[@R46] In the present study, we did not observe significant difference in FABP4 or CD36 mRNA expression in abdominal SAT between IR and healthy participants. In addition, we observed lower fasting fatty acid uptake in VAT and abdominal SAT in IR compared with healthy participants. Interestingly, although the IR group in the present study had significantly higher body adiposity and impaired whole-body insulin sensitivity, we observed no difference in fasting plasma FFA between the groups. At baseline we also found no differences between the groups in genes regulating fatty acid uptake FABP4, CD36 and ANGPTL4. Thus, currently we do not have an explanation as to why the baseline fatty acid uptake uptake was lower in the IR compared with the healthy group.

After training, fatty acid uptake decreased in VAT and tended to decrease in abdominal and femoral SAT in both groups. In SAT biopsies, we found a trend indicating a decreased expression of FABP4 in the IR but not in healthy participants ([figure 7](#F7){ref-type="fig"}). In addition, when studying all IR participants, including women, both training modes led to a decrease in CD36 and ANGPTL4 mRNA expression in abdominal SAT ([figure 7](#F7){ref-type="fig"}). Our results with ANGPTL4 are in agreement with another study where the expression of ANGPTL4 was reduced after 12 weeks of exercise intervention.[@R47] Although there is growing amount of evidence that ANGPTL4 is a key player in angiogenesis,[@R48] the mechanism of reduction in ANGPTL4 expression in adipose tissue in association with exercise training stays unknown. The more pronounced effect of training on VAT fatty acid uptake compared with abdominal and femoral fatty acid uptake could be explained by the notion of VAT being metabolically more active and having a higher expression of β-adrenergic receptors compared with SAT, and thus when stimulated by exercise training this leads to a higher lipolysis.[@R49]

Previous studies have shown a relationship between SAT adipocyte cell size and IR both in VAT and SAT.[@R50] In addition, some studies have found an increased population of small adipocytes (diameter 20--50 µm) in IR and type 2 diabetes.[@R50] It has been suggested that in an IR state the maturation of adipocytes into functional cells is impaired, which results in the accumulation of ectopic fat.[@R54] In the present study, we did not find a baseline difference between the healthy and IR groups as regards the average or median abdominal SAT adipocyte cell size. However, IR participants showed a trend toward an increased fraction of small cells compared with the healthy participants both at baseline and after the exercise training ([figure 4](#F4){ref-type="fig"}). After the training, we did not find a significant change in the mean or median adipocyte size in SAT, despite a small decrease in abdominal SAT mass. Thus, based on our present data and previous data collected by others,[@R56] it seems that longer training interventions and more prominent weight loss are needed to induce changes in adipocyte cell size. Importantly, we observed an increased vasculature in abdominal SAT and decreased VEGF-A levels in plasma, which indicate a better perfusion not only in adipose tissue but also at the whole-body level. This is important, since hypoxia is an important driver of the adipose tissue inflammation observed in obesity and type 2 diabetes. It has been suggested that the crosstalk between adipocytes and vascularization is often lost during adipose tissue expansion in obesity, leading to defective tissue perfusion, hypoxia and inflammation.[@R58] Thus, our present findings indicate that exercise training can promote adipose tissue vascularization and homeostasis.

SIT versus MICT (IR men and women) {#s4-2}
----------------------------------

Several recent studies have shown that high-intensity training can induce improvement in cardiometabolic health indices that are comparable or superior to traditional moderate-intensity training despite the significantly shorter time commitment.[@R60] However, no previous studies have compared the exercise training-induced responses in adipose tissue metabolism and morphology after SIT and MICT in IR participants.

Both SIT and MICT led to similar improvements in whole-body adiposity, insulin sensitivity and femoral SAT glucose uptake. Importantly, both training modes were associated with decreased VAT mass and decreased total and LDL cholesterol, which are known risk factors for cardiometabolic diseases. It is already well recognized that the reduction in VAT mass even independent of weight loss is associated with reduced cardiovascular disease risk.[@R62] We observed significant improvement in VAT glucose uptake only after SIT and VAT fatty acid uptake only after MICT. During exercise, glycogen and lipids are the primary substrates oxidized in the mitochondria to support muscle contraction. The energy used during the lower intensity training is produced mainly from lipids that are hydrolyzed from triglycerides via lipolysis.[@R63] Fat oxidation typically falls as exercise intensity increases from moderate to heavy, after which carbohydrate oxidation becomes primary source of the ATP.[@R64] Therefore, during MICT, energy is mainly produced via fat oxidation, and during SIT via fast glycogen stores, which may explain the different response in VAT fatty acid uptake after SIT and MICT.[@R7]

Women versus men {#s4-3}
----------------

It is well recognized that the fat accumulation in different depots differs between men and women. Men accumulate more VAT, whereas women accumulate more SAT and have a higher percentage of body fat compared with men.[@R65] In the present study, the IR women had a 42% higher body fat content, a 51% higher abdominal SAT volume and a 45% lower VAT volume ([online supplementary table 2](#SP1){ref-type="supplementary-material"}) than the IR men. The women also had a significantly higher VAT glucose uptake ([figure 5](#F5){ref-type="fig"}), VAT fatty acid uptake and femoral SAT fatty acid uptake compared with men. Our results are in line with previous animal and human studies and demonstrate that despite the higher level of total body fat, women are more insulin sensitive than men.[@R20] These findings may be related to sex steroids, which are known to play a role in the regulation of adipose tissue development and function as well as whole-body insulin sensitivity, as it is considered that estrogen might have protective role against IR.[@R20] Despite the significant baseline differences, the only difference between the males and females in the training response was observed in the femoral SAT glucose uptake, which only improved in men. This finding might be explained by higher muscle mass and pain tolerance in men, which allows men to push their limits further, especially during maximal effort in SIT training.

Limitations {#s4-4}
-----------

The major limitation of our study is the relatively small number of participants, although it is in line with previous exercise training studies with similar technically and financially demanding and detailed designs. The statistical significance level was set to 0.05, indicating that there is a 5% risk of finding a false positive result for a given variable. Given the large number of tests performed with a rather small number of subjects, it is possible that some of the findings of this paper may be false positive. Therefore, the results should be considered as hypothesis-generating explorative analysis.

The participants were instructed to maintain their normal eating habits during the study, but nutrition was not controlled. Thus, it might be that some of the study participants increased their food intake as their energy expenditure increased and some may have eaten healthier during the intervention. This could have blunted the effect of intervention for some outcomes.

Conclusion {#s5}
==========

In conclusion, the present study demonstrated that a 2-week short-term supervised, progressive exercise training intervention may improve adipose tissue metabolism both in healthy and IR participants independently of the sex. This study proposes that SIT improves VAT insulin-stimulated glucose uptake more efficiently than MICT, whereas MICT is preferable for VAT fatty acid uptake. Fatty acid uptake in adipose tissue and expression of FATB4, CD36 and ANGPTL4 mRNA decreases and adipose tissue vascularization increases in IR participants with training.
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